- Home
- ATXS vs JMIA Comparison
ATXS vs JMIA Comparison
Compare ATXS & JMIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- JMIA
- Stock Information
- Founded
- ATXS 2008
- JMIA 2012
- Country
- ATXS United States
- JMIA Germany
- Employees
- ATXS N/A
- JMIA N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- JMIA Catalog/Specialty Distribution
- Sector
- ATXS Health Care
- JMIA Consumer Discretionary
- Exchange
- ATXS Nasdaq
- JMIA Nasdaq
- Market Cap
- ATXS 401.2M
- JMIA 412.7M
- IPO Year
- ATXS 2015
- JMIA 2019
- Fundamental
- Price
- ATXS $6.85
- JMIA $7.75
- Analyst Decision
- ATXS Buy
- JMIA Buy
- Analyst Count
- ATXS 6
- JMIA 2
- Target Price
- ATXS $32.00
- JMIA $7.88
- AVG Volume (30 Days)
- ATXS 248.4K
- JMIA 5.3M
- Earning Date
- ATXS 08-12-2025
- JMIA 08-07-2025
- Dividend Yield
- ATXS N/A
- JMIA N/A
- EPS Growth
- ATXS N/A
- JMIA N/A
- EPS
- ATXS N/A
- JMIA N/A
- Revenue
- ATXS N/A
- JMIA $164,022,000.00
- Revenue This Year
- ATXS N/A
- JMIA $8.75
- Revenue Next Year
- ATXS N/A
- JMIA $9.21
- P/E Ratio
- ATXS N/A
- JMIA N/A
- Revenue Growth
- ATXS N/A
- JMIA N/A
- 52 Week Low
- ATXS $3.56
- JMIA $1.60
- 52 Week High
- ATXS $12.92
- JMIA $7.94
- Technical
- Relative Strength Index (RSI)
- ATXS 56.47
- JMIA 82.72
- Support Level
- ATXS $6.60
- JMIA $7.01
- Resistance Level
- ATXS $7.20
- JMIA $7.85
- Average True Range (ATR)
- ATXS 0.47
- JMIA 0.54
- MACD
- ATXS -0.03
- JMIA 0.28
- Stochastic Oscillator
- ATXS 61.72
- JMIA 94.55
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.